BOVILIS® VISION® CD-T WITH SPUR®*
Clostridium Perfringens Types C & D-Tetani Bacterin-Toxoid
Product Description
Shown to be effective for the vaccination of healthy cattle, sheep and goats against disease caused by Clostridium perfringens Types C and D (Enterotoxemia) and Cl. tetani (Tetanus).
Indications
This product has been shown effective for the vaccination of healthy cattle, sheep and goats against Clostridium perfringens Type C & D and C. tetani. This product was licensed prior to the requirement to establish a minimum age for use. Duration of immunity has not been established.
Diseases
A Game-changing Vaccine
Understanding immunology and innovation are critical to addressing emerging diseases and industry challenges through new and improved vaccines.
Merck Animal Health has a history of finding a better way forward through vaccine advancements, and today offers one of the most complete vaccine portfolios.
Learn about BOVILIS VISION from members of the team who brought it to market.
Dosage
Shake well and administer a single 2 mL dose aseptically by subcutaneous route. Repeat the dose in 3 – 4 weeks. For advice on revaccination frequency, contact your veterinarian.
Supplied
1 x 100mL (50 doses)
Preservatives
Contains formaldehyde as a preservative.
Storage
Store at 2°-8°C (35°-46°F). Do not freeze. Use entire contents when first opened.
Safety
Do not mix with other products. Do not vaccinate within 21 days before slaughter. This product has not been tested in pregnant animals. If allergic reaction occurs, treat with epinephrine. In case of human exposure, contact a physician.
FOR ANIMAL USE ONLY
Contact
U.S. only: Merck Animal Health livestocktechsrvc@merck-animal-health.com or call 1-800-211-3573
For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov
For additional information, please see the product label.
References
*Adjuvant-Intervet’s Proprietary Technology.
For more cattle-friendly options, see the rest of the Merck Animal Health vaccine lineup.
Sign up to receive cattle health management insights,
industry news and more sent straight to your inbox.